Experts and Doctors on response evaluation criteria in solid tumors in Houston, Texas, United States

Summary

Locale: Houston, Texas, United States
Topic: response evaluation criteria in solid tumors

Top Publications

  1. Chan J, Deng W, Higgins R, Tewari K, Bonebrake A, Hicks M, et al. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;146:554-559 pubmed publisher
    ..Based on early results of this phase II trial, brivanib was well tolerated and demonstrated sufficient activity after first stage but trial was stopped due to lack of drug availability. ..
  2. Maio M, Scherpereel A, Calabro L, Aerts J, Cedres Perez S, Bearz A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18:1261-1273 pubmed publisher
    ..Investigations into whether immunotherapy combination regimens can provide greater efficacy than monotherapies in malignant mesothelioma are ongoing. AstraZeneca. ..
  3. Woodward W, Fang P, Arriaga L, Gao H, Cohen E, Reuben J, et al. A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer. Int J Radiat Oncol Biol Phys. 2017;99:777-783 pubmed publisher
    ..However, patients with TN breast cancer had poor outcomes even when response was achieved. Further study in non-TN patients may be warranted. ..
  4. Kang H, Gupta S, Wei W, Lu L, Matrana M, Tannir N, et al. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy. AJR Am J Roentgenol. 2017;209:1278-1284 pubmed publisher
    ..The purpose of this study is to compare the prognostic value of various solid tumor response criteria as well as the additive value of clinical risk factors in patients with advanced renal cell carcinoma (RCC)...